Shares of Fulgent Genetics (NASDAQ:FLGT) have been assigned a consensus broker rating score of 3.00 (Hold) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold rating. Fulgent Genetics’ rating score has declined by 50% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokerages have set a twelve-month consensus price target of $4.35 for the company and are forecasting that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also assigned Fulgent Genetics an industry rank of 190 out of 265 based on the ratings given to its competitors.
A number of brokerages have issued reports on FLGT. Zacks Investment Research raised shares of Fulgent Genetics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Credit Suisse Group reduced their price objective on shares of Fulgent Genetics from $6.50 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, March 1st. Finally, Piper Jaffray Companies downgraded shares of Fulgent Genetics from an “overweight” rating to a “neutral” rating in a research report on Thursday, March 1st.
Hedge funds have recently made changes to their positions in the company. Thompson Davis & CO. Inc. bought a new stake in shares of Fulgent Genetics during the 4th quarter valued at $154,000. Royce & Associates LP bought a new stake in shares of Fulgent Genetics during the 4th quarter valued at $219,000. Granahan Investment Management Inc. MA boosted its holdings in shares of Fulgent Genetics by 145.5% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 238,232 shares of the company’s stock valued at $1,141,000 after buying an additional 141,182 shares in the last quarter. Finally, Mutual Advisors LLC bought a new stake in shares of Fulgent Genetics during the 4th quarter valued at $1,662,000. Hedge funds and other institutional investors own 7.94% of the company’s stock.
Shares of Fulgent Genetics (NASDAQ FLGT) traded down $0.18 during trading on Wednesday, reaching $3.85. 8,471 shares of the company’s stock were exchanged, compared to its average volume of 17,796. The stock has a market cap of $68.99, a P/E ratio of -25.87 and a beta of -0.51. Fulgent Genetics has a fifty-two week low of $2.72 and a fifty-two week high of $11.18.
ILLEGAL ACTIVITY WARNING: “Fulgent Genetics (FLGT) Given $4.35 Consensus Target Price by Analysts” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://ledgergazette.com/2018/04/13/fulgent-genetics-flgt-given-4-35-consensus-target-price-by-analysts.html.
Fulgent Genetics Company Profile
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.